Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06966024 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 6 to 8v10
  2. Study sites: 5 to 6v9
  3. Study sites: 4 to 5v8
  4. Study sites: 3 to 4v7
  5. Study sites revised (3)v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 2 to 3v5
  2. Re-verified, no change to tracked fieldsv4
  3. Study sites: 1 to 2
    • Start date changed from estimate of Aug 2025 to Aug 27, 2025
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Secondary endpoints revised (6)
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Trial Details
NCT Number NCT06966024
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions
(from sponsor)		 Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Related terms Carcinoma, Renal Cell, Carcinoma, Transitional Cell
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov